GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges

GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges

GSK plc settles with plaintiff firms representing 80,000 Zantac product liability cases in the U.S., paying up to $2.2 billion. Despite settlements, GSK denies liability and aims to resolve legal uncertainties.

Read More

Did you find this insightful?